Eloxx Pharmaceuticals, Inc.

OTCPK:ELOX Stock Report

Market Cap: US$2.7m

Eloxx Pharmaceuticals Dividends and Buybacks

Dividend criteria checks 0/6

Eloxx Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-257.9%

Buyback Yield

Total Shareholder Yield-257.9%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Sep 14

Eloxx says lead asset failed in mid-stage cystic fibrosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX), a company focused on rare diseases, announced Wednesday that its lead candidate, ELX-02 in combination with ivacaftor, did not achieve efficacy endpoints in a Phase 2 trial involving certain patients with cystic fibrosis (CF). ELOX shares are currently on hold for trading. The study evaluated ELX-02 as monotherapy in combination with ivacaftor in Class 1 CF patients with at least one nonsense genetic mutation. According to topline data, the drug was well tolerated with no treatment-related serious adverse events. However, the trial did not achieve statistical significance for efficacy endpoints, including changes in sweat chloride concentration (SCC) and percent forced expiratory volume (FEV1) from the baseline. Given the safety and signs of clinical activity, ELOX, as previously announced, plans to start a proof-of-concept trial for ELX-02 later this year, targeting patients with the rare kidney disease, Alport syndrome.
Seeking Alpha • Aug 15

Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line

Eloxx Pharmaceuticals press release (NASDAQ:ELOX): Q2 GAAP EPS of -$0.12 in-line. As of June 30, 2022, Eloxx had unrestricted cash and cash equivalents of $30.0M. "As of June 30, 2022, the Company was in compliance with all debt covenants. If our lender does not accelerate our debt upon our failure to comply with the minimum cash covenant, we expect our current cash position will be sufficient to fund our operations into the fourth quarter of 2023," the company statement.
Analysis Article • Sep 09

Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Feb 17

What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?

The big shareholder groups in Eloxx Pharmaceuticals, Inc. ( NASDAQ:ELOX ) have power over the company. Institutions...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ELOX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ELOX's dividend payments have been increasing.

Dividend Yield vs Market

Eloxx Pharmaceuticals Dividend Yield vs Market
How does ELOX dividend yield compare to the market?
SegmentDividend Yield
Company (ELOX)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Pharmaceuticals)2.1%
Analyst forecast (ELOX) (up to 3 years)n/a

Notable Dividend: Unable to evaluate ELOX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ELOX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ELOX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ELOX has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 22:49
End of Day Share Price 2026/05/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eloxx Pharmaceuticals, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yun ZhongBrean Capital Historical (Janney Montgomery)
Mayank MamtaniB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity